[Progression of treatment and researches in dry age related macular degeneration].
Age related macular degeneration (AMD) is the leading cause of blindness and visual disability among old patients in Europe and North America. AMD has been divided into two broad clinical categories depending on whether there is a presence of abnormal neovascularization: neovascular (exudative or wet) AMD and dry (or geographic atrophic) AMD. VEGF has been understood as a pathogenesis of wet AMD which allows us to get breakthroughs in treatment. While the progression of dry AMD treatment is very slow because the lack of pathogenesis, no acute loss of vision, and without appropriate standards for treatment. This review tries to introduce about the recent researches and progressions for dry AMD treatment.
Kaiyan
K
Zhang
Shibo
S
Tang
D035843:Biomedical Research / Q000639:trends*; D001766:Blindness / Q000209:etiology; D006801:Humans; D008268:Macular Degeneration / Q000209:etiology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000209:etiology; D057135:Wet Macular Degeneration / Q000209:etiology / Q000628:therapy; D014985:Xerophthalmia / Q000150:complications*